Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
Healthcare
$2.70 -18.90%
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
52W Low $2.66High $16.00
Volume 0.41M
Average 0.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$36.95M
FY 2025 · Annual
Investing Cash Flow
-$16,000.00
FY 2025 · Annual
Financing Cash Flow
$36.70M
FY 2025 · Annual
-13.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.4M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Depreciation & Amortization | 251.45K | 1.06M | 1.17M | 1.18M | 1.13M |
| Deferred Income Tax | 52.96K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 617.76K | 579K | 1.18M | 1.45M | 2.7M |
| Change in Working Capital | 872.44K | (150K) | (57K) | 3.96M | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30.23K | 1.13M | 23K | (3.33M) | (366K) |
| Other Working Capital | 842.21K | (1.28M) | (80K) | 7.29M | (3.08M) |
| Other Non-Cash Items | 667.05K | 4.54M | 209K | 8.24M | 2.24M |
| Operating Cash Flow | (23.94M) | (22.18M) | (32.69M) | (37.07M) | (36.95M) |
| Capital Expenditures | (525.36K) | (654K) | (66K) | (87K) | (16K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 34K | 3K | 0 |
| Investing Cash Flow | (525.36K) | (654K) | (32K) | (84K) | (16K) |
| Debt Repayment | 14.03M | 0 | 10M | 19.73M | 9.87M |
| Common Stock Issued | 101.38K | 82K | 7M | 5.64M | 26.83M |
| Common Stock Repurchased | 0 | 0 | (150K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 314.88K | 82K | 21.76M | 16.96M | 0 |
| Financing Cash Flow | 19.39M | 21.2M | 38.61M | 42.32M | 36.7M |
| Effect of Forex Changes | 3K | 0 | (68K) | 22K | 40K |
| Net Change in Cash | (5.07M) | (1.63M) | 5.89M | 5.19M | (233K) |
| Free Cash Flow | (24.46M) | (22.83M) | (32.76M) | (37.16M) | (36.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.6M
+ D&A$1.1M
+ Stock-Based Comp$2.7M
+ Deferred Tax$0
- Working Capital-$3.4M
+ Other Non-Cash$2.2M
= Operating Cash Flow-$37.0M
- Capex-$16.0K
= Free Cash Flow-$37.0M
Analysis
FY2025 free cash flow is -$37.0M. FCF conversion is 93.4% of net income. Operating cash flow was -$37.0M, with capex of -$16.0K. The largest bridge item is Working Capital at -$3.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 17, 2026 |
Does ELTX generate free cash flow?
Elicio Therapeutics, Inc. (ELTX) generated -$36.97M of free cash flow in fiscal 2025.
How much operating cash flow does ELTX produce?
Operating cash flow was -$36.95M, before capital expenditures of $16,000.00.
Continue the stock analysis
Jump to another research area for this company.